FcZero-rAb™ PE Anti-Human CD8b Rabbit Recombinant Antibody

CD8b FcZero-rAbTM Recombinant Antibody for FC
Cat No. PE-FcA98103

产品说明书

CloneNo. 241326A7

宿主/亚型

Rabbit / IgG

种属反应性

human

应用

FC

CD8, 241326A7, Ly3, Leu2, CD8B1

缓冲液配方:  PBS and Azide
PBS and Azide
偶联物:  PE
规格: 

-/ -


经过测试的应用

Positive FC detected inhuman PBMCs

推荐稀释比

应用推荐稀释比
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood.
Sample-dependent, Check data in validation data gallery.

产品信息

PE-FcA98103 targets CD8b in FC applications and shows reactivity with human samples.

经测试应用 FC Application Description
经测试反应性 human
免疫原 Recombinant Protein 种属同源性预测
宿主/亚型 Rabbit / IgG
抗体类别 Recombinant
产品类型 Antibody
全称 CD8b molecule
别名 CD8, 241326A7, Ly3, Leu2, CD8B1
计算分子量 243 aa, 27 kDa
GenBank蛋白编号BC100913
基因名称 CD8B
Gene ID (NCBI) 926
偶联类型 PE Fluorescent Dye
最大激发/发射波长496 nm, 565 nm / 578 nm
形式 Liquid
纯化方式Protein A purification
储存缓冲液 PBS with 0.09% sodium azide and 0.5% BSA , pH 7.3
储存条件Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

背景介绍

CD8b (T-cell surface glycoprotein CD8 beta chain) is an integral membrane glycoprotein that forms disulfide-linked heterodimers with CD8a (CD8 alpha chain). The CD8 alpha/beta heterodimer is the predominant CD8 complex expressed on the cell surface (PMID: 1534146; 2111591). CD8 is a transmembrane glycoprotein predominantly expressed on the surface of cytotoxic T cells and can also be found on natural killer cells, cortical thymocytes, and dendritic cells. CD8 serves as a co-receptor for the T cell receptor (TCR). Both CD8 and TCR recognize antigens displayed by an antigen presenting cell (APC) in the context of class I MHC molecules. CD8 plays a role in T cell development and activation of mature T cells.

实验方案

Product Specific Protocols
FC protocol for PE CD8b antibody PE-FcA98103Download protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...